Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 601–700 of 1,010
Zhang, X., Zhu, L., Li, Y., Yu, H., Wang, T., & Chu, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02493-8 · Cited by 21
“Tens of millions of people worldwide currently suffer from Alzheimer’s disease, with projections indicating increasing prevalence in the future, and no definitive cure exists [1].”
Athanasiou, E., Gargalionis, A. N., Anastassopoulou, C. G., Tsakris, A., & Boufidou, F. (2022) · Brain Sciences · doi:10.3390/brainsci12081010 · Cited by 20
“Over a century later, the extracellular senile plaques formed by amyloid beta (Aβ), the intracellular neurofibrillary tangles composed of abnormally hyperphosphorylated tau proteins, and the synaptic loss remain the pathological hallmarks of AD [9,10].”
BackgroundSideritis scardica Extracts Demonstrate Neuroprotective Activity against Aβ25–35 Toxicity
Ververis, A., Ioannou, K., Kyriakou, S., Violaki, N., Panayiotidis, M. I., Plioukas, M., & Christodoulou, K. (2023) · Plants · doi:10.3390/plants12081716 · Cited by 22
“Thus, a pressing need exists to develop a novel therapeutic approach to treat the disease more efficiently [2].”
BackgroundIndanone: a promising scaffold for new drug discovery against neurodegenerative disorders
Bansal, R., Singh, R., Dutta, T. S., Dar, Z. A., & Bajpai, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104063 · Cited by 18
Dolci, G., Cruciani, F., Rahaman, M. A., Abrol, A., Chen, J., Fu, Z., Galazzo, I. B., Menegaz, G., Calhoun, V. D., & Initiative, A. D. N. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/ae087d · Cited by 24
“Amyloid accumulation represents the first event, followed by tau accumulation, hypo-metabolism (assessed with positron emission tomography (PET)), atrophy, and cognitive decline [3, 4].”
Lorenzo, R. D., Zecca, C., Chimienti, G., Latronico, T., Liuzzi, G. M., Pesce, V., Dell’Abate, M. T., Borlizzi, F., Giugno, A., Urso, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167792 · Cited by 18
“Thus, huge attention has been paid by researchers to understanding the etiology and pathogenesis of this multifactorial disease with several risk factors [4].”
Glutathione and neurodegenerative diseases: immunopharmacological implications
Knudsen, E., Tadje, J. E., Coggins, C., & Venketaraman, V. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1737199 · Cited by 26
Neolignans and amide alkaloids from the stems of Piper kadsura and their neuroprotective activity
Chen, H., Zhu, Y., Zhang, Y., Zeng, M., Cao, Y.-G., Sun, P.-T., Cao, B., Du, K., Zhao, X., Wang, X.-W., et al. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113336 · Cited by 18
White matter damage in Alzheimer’s disease: contribution of oligodendrocytes
Zhou, J., Zhang, P., Zhang, B., & Kong, Y. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221021115321 · Cited by 18
Wei, Z., Yang, C., Feng, K., Guo, S., Huang, Z., Wang, Y., & Jian, C. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.078 · Cited by 18
Nowak, I., Madej, M., Secemska, J., Sarna, R., & Strzałka‐Mrozik, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071931 · Cited by 18
“Beta-amyloid protein plays an important role in neurotoxicity and affects neuronal function, so large amounts can lead to axonal damage [57,58].”
BackgroundWan, M., Sun, S., Di, X., Zhao, M., Lu, F., Zhang, Z., & Li, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117029 · Cited by 25
Analyzing alternative splicing in Alzheimer’s disease postmortem brain: a cell-level perspective
Farhadieh, M., & Ghaedi, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1237874 · Cited by 20
“Studies suggest that the loss of ovarian hormones during menopause may increase the risk of AD in women, as androgens play a crucial role in various brain functions, such as neurotransmission, neurodevelopment, survival, protection against oxidative stress, reduction of Aβ peptide levels, and reduced tau hyperphosphor…”
BackgroundPetit, P., Gondard, E., Gandon, G., Moreaud, O., Sauvée, M., & Bonneterre, V. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-023-01079-0 · Cited by 18
“Aging, sex, genetic predisposition, and ancestry are recognized risk factors that are non-modifiable [1, 5, 7, 8].”
BackgroundInfluentialEtiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis
Kamble, S. M., Patil, K. R., & Upaganlawar, A. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00022-4 · Cited by 24
Exploring medical students’ perceptions of empathy after cinemeducation based on Vygotsky’s theory
Salajegheh, M., Sohrabpour, A. A., & Mohammadi, E. (2024) · BMC Medical Education · doi:10.1186/s12909-024-05084-z · Cited by 18
“But, several studies have examined emotions in patients with Alzheimer’s, and the results revealed that these patients have varying degrees of emotion at different stages of the disease [9].”
BackgroundOptimized machine learning model for Alzheimer and epilepsy detection from EEG signals
Sharmila, P. J. J., & Angel, T. S. S. (2024) · Automatika · doi:10.1080/00051144.2023.2297481 · Cited by 19
“Further, to compare the proposed model performance with existing algorithms, the results of Prasanna et al. [30] is used.”
ResultRahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
“Women attribute two-thirds of Alzheimer’s cases to themselves and experience AD more severely than men due to the variation of some genes like ApoE4 and the lack of estrogen secretion during menopause [22, 28].”
Microglial purinergic signaling in Alzheimer’s disease
Mei, S.-Y., Zhang, N., Wang, M., Lv, P.-R., & Liu, Q. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-10029-8 · Cited by 19
“In the absence of effective therapies, the number of people with AD is projected to 150 million in 2050 [3, 4].”
Pterostilbene: A natural neuroprotective stilbene with anti-Alzheimer's disease properties
Gao, S., Zhang, H., Li, N., Zhang, L., Zhu, Z., & Xu, C. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101043 · Cited by 21
“For several years, research has been ongoing to develop drugs to prevent and treat AD; however, no substantial progress has been made so far [10].”
Aishwarya, R., Abdullah, C. S., Remex, N. S., Bhuiyan, M. A. N., Lu, X., Dhanesha, N., Stokes, K. Y., Orr, A. W., Kevil, C. G., & Bhuiyan, M. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-67638-x · Cited by 20
“Aggregation of Aβ and NFTs causes neuronal loss, leading to cognitive impairment 2,3,6,8,9 .”
BackgroundNazir, A., Assad, A., Hussain, A. B., & Singh, M. (2024) · International Journal of Systems Assurance Engineering and Management · doi:10.1007/s13198-024-02441-5 · Cited by 26
Mosharaf, M. P., Alam, K., Gow, J., Mahumud, R. A., & Mollah, M. N. H. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05289-3 · Cited by 18
“AD is an elusive neurodegenerative disease characterized by chronic and persistent cognitive impairment and is considered one of the major causes of dementia [21].”
BackgroundPasupalak, J. K., Rajput, P., & Gupta, G. L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177022 · Cited by 19
Hashmi, M. A. T. S., Fatima, H., Ahmad, S., Rehman, A., & Safdar, F. (2024) · Ibrain · doi:10.1002/ibra.12183 · Cited by 21
Lu, X., Zhang, Y., Tang, Y., Bernick, C. B., & Shan, G. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14393 · Cited by 22
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 20
Neuroprotective potential of hispidulin and diosmin: a review of molecular mechanisms
Singh, A., Singh, L., & Dalal, D. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01615-9 · Cited by 20
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
McDade, E., Liu, H., Bui, Q., Hassenstab, J., Gordon, B. A., Benzinger, T. L. S., Shen, Y., Timsina, J., Wang, L., Sung, Y. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70243 · Cited by 22
Guo, Y., Zhao, J., Liu, X., Lu, P., Liang, F., Wang, X., Wu, J., & Hai, Y. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10165-3 · Cited by 17
“Alzheimer’s disease (AD) is a common neurodegenerative disorder that is projected to affect the health and lives of 152 million people globally by 2050 and increase the burden on society (Breijyeh and Karaman 2020).”
Zhan, H., Cammann, D., Cummings, J. L., Dong, X., & Chen, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06317-5 · Cited by 17
“AD is a complex and multifactorial condition influenced by many risk factors, including genetic, behavioral, environmental, lifestyle, and medical factors, among which genetic risk factors play a crucial role due to the high heritability of AD [7, 8].”
Conway, T., Seidler, K., & Barrow, M. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.09.024 · Cited by 20
Jia, J., Sheng, Z., Zhang, Y., Guo, L., Chen, Z.-L., Zhu, D., Zeng, X., & Liu, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-01636-5 · Cited by 22
“Therefore, it is imperative to develop new and effective prevention and control strategies 25–27 .”
Gagliardi, S., Hotchkin, T., Hillmer, G., Engelbride, M., Diggs, A., Tibebe, H., Izumi, C., Sullivan, C., Cropp, C., Lantz, O., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146724 · Cited by 18
“These conditions arise from a complex interplay of genetic predispositions, environmental exposures, and lifestyle factors, many of which contribute to chronic inflammation within the CNS [14–20].”
Neuroinflammation and nutrition in Alzheimer’s disease
Park, H., Ni, M., & Le, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1622571 · Cited by 17
Zhu, B., Wangzhou, A., Yu, D., Li, T., Schmidt, R., Florencio, S. L. D., Chao, L., Thurber, A. L., Zhou, M., Msheik, Z., et al. (2024) · Neuron · doi:10.1016/j.neuron.2025.06.020 · Cited by 19
Saif, M. S., Batool, S., Majeed, Y., Asadullah, Tariq, T., Li, H., Duan, Y., Mustafa, G., & Hasan, M. (2025) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2025.118725 · Cited by 19
Hong, Y., Choi, Y., Han, Y., Oh, S., Lee, A., Lee, B., Magnan, R., Ryu, S. Y., Choi, C. W., & Kim, M. S. (2021) · Antioxidants · doi:10.3390/antiox10060835 · Cited by 17
“The pathological hallmarks of AD include amyloid-β protein accumulation, tau protein aggregation, excessive oxidative stress, and cholinergic dysfunction [2].”
BackgroundContribution of hyperglycemia-induced changes in microglia to Alzheimer’s disease pathology
Rodríguez, M. H., Flores‐Clemente, C., Macías-Pérez, M. E., Rodríguez-Fonseca, R. A., Nicolás‐Vázquez, M. I., Martínez, J. O., Miranda, R., Rosas, M., & Jiménez, E. M. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00405-9 · Cited by 19
“Indeed, none of the theories proposed to explain the pathology of AD can account for the actual pathological changes known to take place in the brain of AD patients [12].”
BackgroundRosales‐Hernández, M. C., Morales, L. G. F., Correa‐Basurto, J., Valdez, M. O., Baez, E. V. G., Vázquez, D. G. R., García, A. P. A., & Cruz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112945 · Cited by 18
“with several risk factors such as: aging, previous head injuries, vascular risk factors from diabetes, hypercholesterolemia and hypertension [3,4].”
BackgroundEffects of Qi-Fu-Yin on aging of APP/PS1 transgenic mice by regulating the intestinal microbiome
Xiao, Q., Ye, T., Wang, X., Qi, D., & Cheng, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1048513 · Cited by 18
“Age is the most important factor influencing the onset of AD, and the incidence of AD increases with age (Breijyeh and Karaman, 2020; Qiu et al., 2009).”
BackgroundSato, Y., Terawaki, S., Oikawa, D., Shimizu, K., Okina, Y., Ito, H., & Tokunaga, F. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1089213 · Cited by 18
“Memantine has been approved as an N-methyl D-aspartate (NMDA) antagonist, and monoclonal antibodies such as Aducanumab, Gantenerumab, and so on, which target and remove β-amyloid, are expected to be effective diseasemodifying therapeutics (Breijyeh and Karaman 2020).”
BackgroundMa, K., Zheng, Z.-R., & Meng, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041459 · Cited by 20
“Both mechanisms may be linked to symptoms of AD including progressive memory loss, cognitive decline, and learning difficulties [76,77].”
BackgroundRecent advances of PROTACs technology in neurodegenerative diseases
Wang, C., Zhang, Y., Yang, S., & Xing, D. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105015 · Cited by 19
Gul, S., Attaullah, S., Alsugoor, M. H., Bawazeer, S., Shah, S. A., Khan, S., Salahuddin, H. S., & Ullah, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16930 · Cited by 18
“When formation of neurofibrillary tangles occurs within neurons it causes microtubule destabilizations, neuronal and synaptic injury [24,25].”
BackgroundTargeting mGluR group III for the treatment of neurodegenerative diseases
Rabeh, N., Hajjar, B. M., Maraka, J. O., Sammanasunathan, A. F., Khan, M., Alkhaaldi, S. M. I., Mansour, S., Almheiri, R. T., Hamdan, H., & Abd‐Elrahman, K. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115733 · Cited by 18
Davidson, R., Krider, R. I., Borsellino, P., Noorda, K., Alhwayek, G., & Vida, T. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110553 · Cited by 17
“Alzheimer’s disease (AD) is the most common form of dementia [1].”
BackgroundMulti-perspective neural network for dual drug repurposing in Alzheimer’s disease
Zhao, L., Li, Z., Chen, G., Yin, Y., & Chen, C. Y. (2023) · Knowledge-Based Systems · doi:10.1016/j.knosys.2023.111195 · Cited by 17
Ren, J., & Xiao, H. (2023) · Life · doi:10.3390/life13122285 · Cited by 22
“Alzheimer’s disease (AD) is one of the major challenges in the field of public health, characterized by a gradual decline in cognitive function and memory [1,2].”
BackgroundMonoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 18
Xie, J., Cheng, J., Ko, H., & Tang, Y. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00046-w · Cited by 18
“Amyloid-β protein plaques and abnormal phosphorylated tau protein that forms neuro fi brillary tangles are characterized as pathological features and likely contribute to the development of AD (Breijyeh and Karaman, 2020).”
BackgroundWang, Y., Zhao, M., Xie, C., Li, L., Lin, L., Li, Q., Li, L., Chen, F., Yang, X., Yang, J., et al. (2024) · Foods · doi:10.3390/foods13132154 · Cited by 20
Phytotherapy in Alzheimer’s Disease—A Narrative Review
Piekarz, J., Picheta, N., Burdan, O., Kurek, M., & Chrościńska–Krawczyk, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081812 · Cited by 20
“It undergoes cleavage by β -secretases, resulting in non-toxic fragments, while when cleaved first by β -secretases and then by γ -secretases, neurotoxic beta-amyloid 42 is formed [15].”
BackgroundShah, S., & Shah, M. (2024) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2024.08.004 · Cited by 22
Early diagnosis of Alzheimer’s Disease based on multi-attention mechanism
Yang, X., Hong, K., Zhang, D., & Wang, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310966 · Cited by 25
“These neurological functional abnormalities have a significant impact on the daily life of the patients [1].”
BackgroundThe Mediterranean Diet: A powerful defense against Alzheimer disease–A comprehensive review
Vaziri, Y. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.09.020 · Cited by 18
Ebrahimi, M., Akhavan, O., & Li, R. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.156888 · Cited by 18
Rakshit, D., Goyal, R., Yadav, V. K., Gore, S. K., Sen, S., Ranjan, O. P., & Mishra, A. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419814 · Cited by 17
Ashwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
“A b 42 amplifies the development of b -amyloid fi-brils from senile plaques, subsequently causing tau pathology and neurotoxicity, resulting in cell apoptosis and neurodegeneration 7 .”
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
Aye, S., Johansson, G., Höck, C., Lannfelt, L., Sims, J. R., Blennow, K., Frederiksen, K. S., Graff, C., Molinuevo, J. L., Scheltens, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100022 · Cited by 21
Ratne, N., Jari, S., Tadas, M., Katariya, R., Kale, M. B., Kotagale, N. R., Madia, D., Umekar, M. J., & Taksande, B. G. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102687 · Cited by 19
Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer’s Disease—Are There Connections?
Fułek, M., Hachiya, N., Gachowska, M., Beszłej, J. A., Bartoszewska, E., Kurpas, D., Kurpiński, T., Adamska, H., Poręba, R., Urban, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052097 · Cited by 18
“AD is a multifactorial illness that causes cell degeneration in the brain and is the leading cause of dementia, which is defined by a loss of cognitive ability and independence in everyday tasks [28].”
Dysregulated ac4C modification of mRNA in a mouse model of early-stage Alzheimer’s disease
Ji, H., Zhou, H.-Q., Qie, J., Lu, W.-M., Gao, H., & Wu, D. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01389-8 · Cited by 17
“Understanding the pathological alterations occurring in the early-stages of AD—when cognitive function is largely preserved—is particularly important [4, 5].”
Khan, B., Iqbal, M. K., Khan, M. A., Khan, H. R., Kiyani, M. M., Bashir, S., & Li, S. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02337-4 · Cited by 17
“Alzheimer’s disease (AD) has a multifactorial etiology with an intricate web of environmental, lifestyle, and comorbid factors (Breijyeh and Karaman 2020).”
Abondio, P., Sarno, S., Giuliani, C., Laganà, V., Maletta, R., Bernardi, L., Bruno, F., Colao, R., Puccio, G., Frangipane, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines10010020 · Cited by 17
“(APP) located on chromosome 21; indeed, at least twenty-five mutations in the APP gene have been related to AD so far [5].”
BackgroundGu, X., Zhang, G., Qin, Z., Yin, M., Chen, W., Zhang, Y., & Liu, X. (2022) · Bioengineered · doi:10.1080/21655979.2021.2022262 · Cited by 18
“It has become a public health crisis since the total number of older people is likely to significantly increase in upcoming decades [2].”
BackgroundRetractedAltered Mitochondrial Protein Homeostasis and Proteinopathies
Jishi, A., & Qi, X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.867935 · Cited by 19
Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
Gong, X., Zhang, H., Liu, X., Liu, Y., Liu, J., Fapohunda, F. O., Lü, P., Wang, K., & Tang, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977999 · Cited by 19
“These plaques are mainly comprised of neurotoxic amyloid-beta protein 40 (Aβ40) and amyloid-beta protein 42 (Aβ42), which would have a devastating effect on neuronal cells (Hodson, 2018; Breijyeh and Karaman, 2020).”
BackgroundRichter-Laskowska, M., Sobotnicka, E., & Bednorz, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-90460-y · Cited by 16
“Future studies should consider a larger number of comorbidities, including estimates of their duration, and incorporate additional environmental variables, such as exposure to heavy metals, pesticides, medical factors like infectious diseases 17 , and polypharmacy 18,61 .”
InfluentialPolypharmacology and Neuroprotective Effects of Gingerol in Alzheimer’s Disease
Priyadarshini, S., Goyal, K., Roopashree, R., Gupta, S. K., Roy, A., Biswas, R., Patra, S., Chauhan, P., Wadhwa, K., Singh, G., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04484-y · Cited by 17
“AD is the primary cause of dementia in older people and is a progressive NDs [31, 32].”
Huang, J., Lai, L., Su, Y., Chen, J., Li, P., & Du, B. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116087 · Cited by 16
Emerging Roles of Metallothioneins in Human Pathophysiology: A Review
Mohammed, O., Tufa, A., & Gizaw, S. T. (2025) · Health Science Reports · doi:10.1002/hsr2.71279 · Cited by 19
“MT1/2 are upregulated near amyloid plaques, especially in the hippocampus and cortex, suggesting involvement in AD pathogenesis [97, 100 – 103].”
González-Naranjo, P., Pérez, C., González‐Sánchez, M., Gironda-Martínez, A., Ulzurrun, E., Bartolomé, F. B., Rubio‐Fernández, M., Martín, M. I., Campillo, N. E., & Paez, J. A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2117315 · Cited by 17
A Review on Phyto-Therapeutic Approaches in Alzheimer’s Disease
Sahiner, M., Yilmaz, A. S., Güngör, B., & Şahiner, N. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14010050 · Cited by 16
“It has not been fully elucidated how genetic factors are involved in the etiology [6,11,30].”
BackgroundInfluentialRegenerative marine waste towards CaCO3 nanoformulation for Alzheimer's therapy
Nallasamy, P., Rajamohamed, B. S., Jeyaraman, J., Brindhadevi, K., & Suganthy, N. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115631 · Cited by 16
DNA methylation: The epigenetic mechanism of Alzheimer's disease
Qin, H., Liu, J., Fang, C., Deng, Y., & Zhang, Y. (2023) · Ibrain · doi:10.1002/ibra.12121 · Cited by 16
“13 It is characterized by neuritic plaques and neurofibrillary tangles.”
BackgroundWang, Y., Shen, Z., Wu, H., Yu, Z., Wu, X., Zhou, L., & Guo, F. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148545 · Cited by 16
Ng, A. N., Salter, E. W., Georgiou, J., Bortolotto, Z. A., & Collingridge, G. L. (2023) · iScience · doi:10.1016/j.isci.2023.108412 · Cited by 18
Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models
Fang, X., Fan, F., & Roman, R. J. (2024) · Journal of Experimental Neurology · doi:10.33696/neurol.5.087 · Cited by 20
“AD is characterized by the accumulation of extracellular A β plaques and intracellular phosphorylated-tau protein, which lead to progressive neuronal loss and cognitive decline [101].”
BackgroundLattice 123 pattern for automated Alzheimer’s detection using EEG signal
Doğan, Ş., Barua, P. D., Bayğın, M., Tuncer, T., Tan, R., Ciaccio, E. J., Fujita, H., Devi, A., & Acharya, U. R. (2024) · Cognitive Neurodynamics · doi:10.1007/s11571-024-10104-1 · Cited by 16
Shields, R. K., Horcajada, J. P., Kamat, S., Irani, P. M., Tawadrous, M., & Welte, T. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00999-y · Cited by 16
A comprehensive update on cannabidiol, its formulations and drug delivery systems
Banerjee, S., Saharan, V. A., Banerjee, D., Ram, V., Kulhari, H., Pooja, D., & Singh, A. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10001-9 · Cited by 16
Lim, L. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1407785 · Cited by 16
Developing diagnostic biomarkers for Alzheimer's disease based on histone lactylation-related gene
Guo, S., Zhu, W., Bian, Y., Li, Z., Zheng, H., Li, W., Yang, Y., Ji, X., & Zhang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37807 · Cited by 17
“Two primary hypotheses for the cause of AD are the cholinergic hypothesis and the amyloid hypothesis, with symptoms worsening with age [28].”
BackgroundThe cross-talk between ApoE and Tau protein in Alzheimer’s disease
Chinnathambi, S., Kumarappan, M., & Chandrashekar, M. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.08.004 · Cited by 25
Jain, S., Bhushan, B., Mishra, A. K., & Singh, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106413 · Cited by 20
Nagori, K., Nakhate, K. T., Yadav, K., Thakur, A., Ajazuddin, M., & Pradhan, M. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.113604 · Cited by 17
Understanding the Molecular Impact of Physical Exercise on Alzheimer’s Disease
Cantón-Suárez, A., Sánchez-Valdeón, L., Bello-Corral, L., Cuevas, M. J., & Estébanez, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413576 · Cited by 17
“Nevertheless, there is currently no accepted theory to explain the pathogenesis of AD [22,23].”
Abu‐Elfotuh, K., Mahran, Y., Gazzar, W. B. E., Youssef, H. S., Hamdan, A. M., Albalawi, T. M., Alsunbul, M., Alqahtani, R. A., & Mohammed, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031260 · Cited by 19
“Even though AD is a public health issue, the available drugs are only symptomatic [56,57].”
Ghadami, R., & Rahebi, J. (2025) · Diagnostics · doi:10.3390/diagnostics15030377 · Cited by 17
“In individuals with Alzheimer’s, abnormal protein formations such as amyloid plaques and neurofibrillary tangles develop in and around neurons in specific areas of the brain [29].”
Shrief, A. I., Elshenawy, D. S. A., Elsukary, A. E., Elekhtiar, S. A., & Yahia, O. A. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10361-2 · Cited by 17
“Regardless of continuous research, the exact etiological factors of AD remain unknown (Breijyeh and Karaman 2020).”
Ho, N. T. N., Gonzalez, P., & Gogovi, G. K. (2025) · Healthcare Technology Letters · doi:10.1049/htl2.70006 · Cited by 20
Chen, S., Wu, L., Lang, B., Zhao, G., & Zhang, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516991 · Cited by 19
“Alzheimer ’ s disease (AD) is the most common age-related neurodegenerative disease and often presents with dementia (Breijyeh and Karaman, 2020).”
Batool, S., Furqan, T., Mahmood, M. S. H., Tweedie, D., Kamal, M. A., & Greig, N. H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00200 · Cited by 17
Li, M., Cheng, W., Zhang, L., Zhou, C., Peng, X., Yu, S., & Zhang, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810766 · Cited by 19
“Currently, there are about 50 million people diagnosed with AD worldwide, and it is estimated that the number will double every 5 years, reaching 152 million by 2050 [2].”
BackgroundRole of Necroptosis in Central Nervous System Diseases
Shao, H., Wu, W., Wang, P., Han, T., & Zhuang, C. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00405 · Cited by 16
Bhachawat, S., Shriram, E., Srinivasan, K., & Hu, Y. (2023) · Diagnostics · doi:10.3390/diagnostics13020288 · Cited by 18
“A variety of cellular-level processes might be the trigger for causing ALS pathomechanisms but a single gene with direct metabolic disturbance has not been found or linked yet [26].”
BackgroundResmi, A. N., Rekha, C. R., Dhushyandhun, M. E., Sarathkumar, E., Shenoy, S. J., Gulia, K. K., & Jayasree, R. S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02802f · Cited by 16
Wang, Z., Zhang, D., Cheng, C., Lin, Z., Zhou, D., Sun, Y., Li, W., Yan, J., Luo, S., Qian, Z., et al. (2023) · Nutrients · doi:10.3390/nu15194244 · Cited by 16
“Drugs approved for treating AD primarily target symptomatic relief without providing a cure or preventive measures against the underlying disease [6].”
Recent progresses in natural based therapeutic materials for Alzheimer's disease
Zivari‐Ghader, T., Valioğlu, F., Eftekhari, A., Aliyeva, I., Beylerli, O., Davran, S., Cho, W. C. S., Beilerli, A., Khalilov, R. I., & Javadov, S. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26351 · Cited by 19
“Regardless of their beneficial effects, these drugs only cure the AD symptoms [16,43].”
BackgroundInfluential
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.